russ2000_2_0189|CYCN|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|price_next_month|price_second_month
russ2000_2_0189|CYCN|1|Cyclerion Therapeutics Inc Total Current Assets (Quarterly) (USD)|Cyclerion Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Cyclerion Therapeutics Inc Inventories (Quarterly) (USD)|Cyclerion Therapeutics Inc Net PP&E (Quarterly) (USD)|Cyclerion Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Cyclerion Therapeutics Inc Total Liabilities (Quarterly) (USD)|Cyclerion Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Cyclerion Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Cyclerion Therapeutics Inc Total Deposits (Quarterly) (USD)|Cyclerion Therapeutics Inc Book Value (Quarterly) (USD)|Cyclerion Therapeutics Inc Retained Earnings (Quarterly) (USD)|Cyclerion Therapeutics Inc Treasury Stock (Quarterly) (USD)|Cyclerion Therapeutics Inc EV to Revenues|Cyclerion Therapeutics Inc EV to Earnings|Cyclerion Therapeutics Inc EV to Free Cash Flow|Cyclerion Therapeutics Inc EV to Assets (Quarterly)|Cyclerion Therapeutics Inc PS Ratio|Cyclerion Therapeutics Inc PE Ratio|Cyclerion Therapeutics Inc Price to Book Value|Cyclerion Therapeutics Inc PEG Ratio|Cyclerion Therapeutics Inc Debt to Equity Ratio|Cyclerion Therapeutics Inc Dividend Yield|Cyclerion Therapeutics Inc Shareholder Yield (TTM)|Cyclerion Therapeutics Inc Percent of Shares Outstanding Short|Cyclerion Therapeutics Inc Total Receivables (Quarterly) (USD)|Cyclerion Therapeutics Inc Total Payables (Quarterly) (USD)|Cyclerion Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Cyclerion Therapeutics Inc Return on Invested Capital|Cyclerion Therapeutics Inc Quality Ratio Score|Cyclerion Therapeutics Inc Momentum Score|Cyclerion Therapeutics Inc Beta (1Y)|Cyclerion Therapeutics Inc Sustainable Growth Rate (TTM)|Cyclerion Therapeutics Inc Institutional Investor Ownership Percentage|Cyclerion Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Cyclerion Therapeutics Inc Total Employees (Annual)|Cyclerion Therapeutics Inc EPS Diluted (Quarterly) (USD)|Cyclerion Therapeutics Inc Shares Outstanding|Cyclerion Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Cyclerion Therapeutics Inc Ordinary Shares Number (Quarterly)|Cyclerion Therapeutics Inc Payout Ratio|Cyclerion Therapeutics Inc Quick Ratio (Quarterly)|Cyclerion Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Cyclerion Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Cyclerion Therapeutics Inc Effective Tax Rate (TTM)|Cyclerion Therapeutics Inc Return on Equity|Cyclerion Therapeutics Inc Net Income (TTM) (USD)|Cyclerion Therapeutics Inc Revenue (TTM) (USD)|Cyclerion Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Cyclerion Therapeutics Inc Revenue (Quarterly) (USD)|Cyclerion Therapeutics Inc Gross Profit (Quarterly) (USD)|Cyclerion Therapeutics Inc SG&A Expense (Quarterly) (USD)|Cyclerion Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Cyclerion Therapeutics Inc Net Income (Quarterly) (USD)|Cyclerion Therapeutics Inc Net Interest Income (Quarterly) (USD)|Cyclerion Therapeutics Inc Price (USD)|Cyclerion Therapeutics Inc Total Return Price (USD)|Cyclerion Therapeutics Inc Enterprise Value (USD)|Cyclerion Therapeutics Inc 30-Day Average Daily Volume|Cyclerion Therapeutics Inc 1 Year Price Returns (Daily)||
russ2000_2_0189|CYCN|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric||
russ2000_2_0189|CYCN|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily||
russ2000_2_0189|CYCN|5|91.1666666667|91.1666666667|0|91.1666666667|0|91.1666666667|91.1666666667|91.1666666667|0|91.1666666667|91.1666666667|0|1.43055555556|91|1.43734643735|91.5|1.43055555556|0|1.44144144144|0|91.5|1.44088669951|91|15.2571428571|91.1666666667|91.1666666667|91.1666666667|91|0|30.6|30.5|91|30.5|91.3333333333|365|91.3333333333|31.3125|0|91.1666666667|91|91.5|91.3333333333|91.375|0|91|91.1666666667|91|0|91.5|0|91.3333333333|91.3333333333|91.3333333333|91.375|1.44088669951|1.44088669951|1.43734643735|1.44031830239|1.43137254902||
russ2000_2_0189|CYCN|6|6|6|0|6|0|6|6|6|0|6|6|0|144|1|407|4|144|0|333|0|4|406|1|35|6|6|6|1|0|5|6|1|2|9|1|9|16|0|6|1|4|9|8|0|1|6|1|0|4|0|9|9|9|8|406|406|407|377|153||
russ2000_2_0189|CYCN|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily||
russ2000_2_0189|CYCN|201803||||||||||||||||||||||||||||||||||27.304||-0.926||||||-0.926|||||||||3.769|-25.283|-25.283||||||||
russ2000_2_0189|CYCN|201806||||||||||||||||||||||||||||||||||27.304||-1.0907||||||-1.0907|0||||||||7.53|-29.781|-29.781|0|||||||
russ2000_2_0189|CYCN|201809||||||||||||||||||||||||||||||||||27.304||-1.0726||||||-1.0726|0||||||||7.787|-29.286|-29.286|0|||||||
russ2000_2_0189|CYCN|201812|0.879|0||6.497||17.846|17.846|0||-10.445|0||||||||||||||0|2.781|0|||||||27.3045|140|-1.1318|||27.4112|||-1.1318|0|||-115.252|||||8.45|-30.902|-30.902|0|||||||
russ2000_2_0189|CYCN|201903|0.939|||8.815||17.525|17.473|0.052||-7.752|||||-5.6886|||||||0||4.9617||5.671||||||||27.38||-1.37|27.3045||27.4017|||-1.37||||-127.35|||||10.977|-37.381|-37.381|0|19|19|518.7855|176037.5667||15.23|15
russ2000_2_0189|CYCN|201906|144.693|141.03||83.084||94.313|21.916|72.397||141.19|-32.254||||-2.7914|0.7339|||1.8774||0|0||3.3315|1.857|8.783|0|||||||27.393||-1.18|27.4112||27.4112||6.5198|-1.18|-175|||-129.823|||1.628||8.923|-32.254|-32.254|0.8|11.25|11.25|308.2691|189675.2||9.65|8.79
russ2000_2_0189|CYCN|201909|120.706|117.034||81.272||90.507|19.096|71.411||119.197|-59.572||||-2.1547|1.0295|||2.7345||0|0||4.4921|1.44|5.005|0|||||||27.434||-1|27.4684||27.4684||6.2041|-1|0|||-127.854|||1.398||7.119|-27.317|-27.317|0.699|14.08|14.08|245.0563|114748.4333||13.43|1.82
russ2000_2_0189|CYCN|201912|101.197|94.895||79.75||88.749|18.249|70.5||97.729|-85.627||||0.391|-0.1063|||0.6153||0|0||2.8119|1.474|3.311|0|||||||27.38|94|-0.95|27.5981||27.5981||5.2808|-0.95|0|||-123.007|||1.481||7.385|-26.055|-26.055|0.531|2.72|2.72|-43.692|900320.8||3.5|4.26
russ2000_2_0189|CYCN|202003|70.126|67.096||63.854||58.49|11.435|47.055||81.54|-105.855||1.1691|-0.061|0.043|0.0461|13.1847||0.923||0|0|-237.9318|5.4076|1.026|1.522|0|-96.3062||1|-0.2716|-122.5434||27.669||-0.73|27.7549||27.7549|0|5.9573|-0.8064|||-122.5434|-105.854|5.521||1.014||6.891|-20.228|-20.228|0.361|2.65|2.65|-4.6916|545970.9667|-87.399|3.53|4.29
russ2000_2_0189|CYCN|202006|59.562|56.462||62.093||61.937|15.645|46.292||66.101|-125.389||24.0599|-1.1992|-1.1205|0.8723|35.0991||2.2465||0.0531|0|-0.4263|3.7434|0.751|2.588|0|-91.4394||1|1.7626|-92.0739|96.224|27.791||-0.7|27.8577||27.8577|0|3.657|-0.7|0||-92.0739|-93.134|4.642||0.749||6.627|-19.534|-19.534|0.138|5.91|5.91|116.0863|278370.5667|-48.3843|3.6|6.71
russ2000_2_0189|CYCN|202009|70.124|66.84||54.576||56.048|16.262|39.786||75.354|-144.201||39.2853|-1.6916|-1.9863|1.0894|47.9426||3.4895||0.0466|0|-12.084|2.7617|0.4|1.855||-94.6762||3|2.1254|-96.1866|91.605|32.096||-0.59|33.9616||33.9616||4.1348|-0.6657|-24.25||-96.1866|-84.629|3.644||0.4||8.033|-18.812|-18.812|0.093|6.89|6.89|182.114|247361.3|-49.835|2.5|2.98
russ2000_2_0189|CYCN|202012|58.501|54.395||50.267||55.885|16.952|38.933||59.493|-163.429||23.2137|-0.6851|-0.4645|0.4619|40.509||1.3476||0.059||-23.9496|1.7123|0.127|1.435||-99.5562||9|2.6644|-102.3126||34.024|34|-0.55|34.0473||34.0473||3.2163|-0.55|||-102.3126|-77.802|2.296||0.133||7.265|-19.228|-19.228|-0.004|3|3|38.2151|341817.8333|12.5|3.17|3.94
russ2000_2_0189|CYCN|202103|44.446|41.429||49.003||51.534|13.467|38.067||48.433|-176.828||42.6357|-0.8074|-0.5529|0.5732|66.4244||1.5432||0.0725||-26.2037|2.2541||1.095||-102.8722||2|4.2588|-107.2356||34.081||-0.39|34.1299||34.1299||3.0763|-0.39|||-107.2356|-70.973|1.344||0.062||5.365|-13.399|-13.399|-0.004|2.69|2.69|40.9234|297919.5333|5.283|2.56|2.96
russ2000_2_0189|CYCN|202106|72.989|70.39||0.153||10.51|10.51|||65.222|-193.01||28.3428|-1.5068|-2.1242|1.3454|36.8596||3.3216||0.0538||-32.854|4.3034||1.386||-101.7935||2|3.4565|-107.4704|83.3296|35.707||-0.45|43.2752||43.2752||6.6974|-0.4253|-30.497||-107.4704|-67.621|3.595||3||6.241|-16.182|-16.182|-0.006|3.98|3.98|122.9552|2092567.7333|-34.0102|3.24|3.42
russ2000_2_0189|CYCN|202109|63.682|62.503||1.561||11.355|11.355|||56.387|-204.3||20.8772|-1.2308|-1.5642|1.0919|31.8661||2.2029||0.0622||-22.9411|2.6738|0.158|1.174||-93.1958||1|2.576|-98.5588|81.6016|43.291||-0.26|43.3101||43.3101||5.5184|-0.26|-0.006||-98.5588|-60.099|3.543||0.348||4.601|-11.29|-11.29|-0.005|3.32|3.32|76.7976|358406.5333|-49.5066|2.72|2.18
russ2000_2_0189|CYCN|202112|||||||||||||4.3774||-0.2044||17.8533||1.1984|||||1.4425||||||2|-1.8097||80.8289||||||||||||||||||||||1.56|1.56|8.5785|464775.5667|-43.7908|1.07|1.21